Immunopathogenesis of HIV/hepatitis C virus coinfection

Author： MacParland Sonya A Vali Bahareh Ostrowski Mario A

ISSN： 1746-0794

Source： Future Virology, Vol.6, Iss.9, 2011-09, pp. : 1115-1128

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of HIV and hepatitis virus coinfection

By Mendes-Corrêa MariaCássia Núñez Marina

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 15, 2010-10 ,pp. : 2497-2516

Informa Healthcare

Access to resources Recommend Favorite

Challenges in the Management of HIV and Hepatitis C Virus Co-infection

By Lee W. Dieterich D.

Drugs, Vol. 64, Iss. 7, 2004-01 ,pp. : 693-700

Adis International

Access to resources Recommend Favorite

Opportunities in proteomics to understand hepatitis C and HIV coinfection

By Meissner Eric G Suffredini Anthony F Kottilil Shyamasundaran

Future Virology, Vol. 7, Iss. 8, 2012-08 ,pp. : 759-765

Future Medicine

Access to resources Recommend Favorite

Peginterferon- -2a (40kD) Plus Ribavirin: A Review of its Use in Hepatitis C Virus and HIV Co-infection

By Plosker Greg L. Keating Gillian M.

Drugs, Vol. 64, Iss. 24, 2004-01 ,pp. : 2823-2843

Adis International

Access to resources Recommend Favorite

Use of Baraclude [entecavir] is not recommended in patients with HIV/hepatitis B coinfection who are not receiving HAART

Reactions Weekly, Vol. 1, Iss. 1166, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite